section name header

Information

  1. Hemodynamics
    1. Volatile anesthetics produced dose-dependent and similar decreases in systemic blood pressure (Fig. 17-6: Heart rate and systemic blood pressure changes (from awake baseline) in volunteers receiving general anesthesia with a volatile anesthetic). The primary mechanism to decrease blood pressure with increasing dose is related to their potent effects to lower regional and systemic vascular resistance (Fig. 17-7: Cardiac index (CI), systemic vascular resistance (SVR), and central venous pressure (CVP) changes from awake baseline in volunteers receiving general anesthesia with a volatile anesthetic).
    2. In volunteers, sevoflurane to about 1 MAC results in minimal changes in heart rate; isoflurane and desflurane are associated with an increase of 5% to 10% from baseline 10 to 15 (see Fig. 17-6: Heart rate and systemic blood pressure changes (from awake baseline) in volunteers receiving general anesthesia with a volatile anesthetic).
      1. Rapid increases in the delivered concentration of desflurane (and to a lesser extent, isoflurane) may transiently increase heart rate and systemic blood pressure.
      2. Administration of an opioid or clonidine blunts the heart rate responses evoked by volatile anesthetics, including responses associated with abrupt increases in the delivered concentration of volatile drug.
  2. Myocardial Contractility. Human studies with isoflurane, sevoflurane, and desflurane have not demonstrated significant changes in echocardiographic-determined indices of myocardial function.
  3. Other Circulatory Effects
    1. Nitrous oxide is associated with increased sympathetic nervous system activity when administered alone or in combination with other volatile anesthetics.
    2. Isoflurane, sevoflurane, and desflurane do not predispose patients to ventricular arrhythmias or sensitize the heart to the arrhythmogenic effects of epinephrine.
  4. Coronary Steal, Myocardial Ischemia, and Cardiac Outcomes
    1. Most potent volatile anesthetics increase coronary blood flow beyond that of myocardial oxygen demand. (No evidence that coronary steal occurs with resulting increased incidence of myocardial infarction or perioperative death.)
    2. Myocardial ischemia and cardiac outcome seem more related to events that alter myocardial oxygen delivery rather than the specific anesthetic drug selected.
  5. Cardioprotection from Volatile Anesthetics
    1. Volatile anesthetics mimic ischemia preconditioning and initiate a cascade of intracellular events resulting in myocardial protection against ischemia and reperfusion injury that last beyond elimination of the anesthetic.
    2. It is likely that anesthetic cardioprotection lessens myocardial damage (based on troponin levels) during cardiac surgery with or without cardiopulmonary bypass.
    3. Sulfonylurea oral hyperglycemic drugs close KATP channels and abolish anesthetic preconditioning. Hyperglycemia also prevents preconditioning, so insulin therapy should be started when oral agents are discontinued before surgery.
    4. Recent evidence suggests that volatile anesthetics, including xenon, may protect other organs from ischemic injury, including the kidneys, liver, and brain.
  6. Autonomic Nervous System
    1. Isoflurane, desflurane, and sevoflurane produce similar dose-dependent depression of reflex control of sympathetic nervous system outflow.
    2. Desflurane is unique in evoking increased sympathetic nervous system outflow (paralleled by increased plasma concentrations of catecholamine) when the delivered concentration of this drug is abruptly increased (Fig. 17-8: Stress hormone responses to a rapid increase in anesthetic concentration from 4% to 12% inspired).

Outline

Inhaled Anesthetics

  1. Pharmacokinetic Principles
  2. Clinical Overview of Current Inhaled Anesthetics
  3. Neuropharmacology of Inhaled Anesthetics
  4. The Circulatory System
  5. The Pulmonary System
  6. Hepatic Effects
  7. Neuromuscular System and Malignant Hyperthermia
  8. Genetic Effects, Obstetric Use, and Effects on Fetal Development
  9. Anesthetic Degradation by Carbon Dioxide Absorbers
  10. Anesthetic Metabolism
  11. Clinical Utility of Volatile Anesthetics
  12. Pharmacoeconomics and Value-Based Decisions